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Background: Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The
prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker
for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for
human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and
CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human
chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to
take advantage of the unique properties of IgE in order to trigger immune activation against PCa.
Methods: Binding characteristics of the antibody were determined by ELISA and flow cytometry. In vitro
degranulation was determined by the release of β-hexosaminidase from effector cells. In vivo degranulation was
monitored in human FcεRIα transgenic mice using the passive cutaneous anaphylaxis assay. These mice were also
used for a vaccination study to determine the in vivo anti-cancer effects of this antibody. Significant differences in
survival were determined using the Log Rank test. In vitro T-cell activation was studied using human dendritic cells
and autologous T cells.
Results: The anti-PSA IgE, expressed in murine myeloma cells, is properly assembled and secreted, and binds the
antigen and FcεRI. In addition, this antibody is capable of triggering effector cell degranulation in vitro and in vivo
when artificially cross-linked, but not in the presence of the natural soluble antigen, suggesting that such an
interaction will not trigger systemic anaphylaxis. Importantly, the anti-PSA IgE combined with PSA also triggers
immune activation in vitro and in vivo and significantly prolongs the survival of human FcεRIα transgenic mice
challenged with PSA-expressing tumors in a prophylactic vaccination setting.
Conclusions: The anti-PSA IgE exhibits the expected biological properties and is capable of triggering immune
activation and anti-tumor protection. Further studies on this antibody as a potential PCa therapy are warranted.
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Prostate cancer (PCa) is the most frequently diagnosed
cancer and the second leading cause of cancer deaths
among men in the USA, with an estimated 241,740 new
cases and 28,170 deaths in 2012 [1]. At its early stages,
localized PCa can be curable in many cases by treatments
such as surgery or radiation [2]. PCa that relapses or is* Correspondence: tdaniels@mednet.ucla.edu
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distribution, and reproduction in any mediumfound to be metastatic at diagnosis may be treated with
androgen deprivation therapy [3,4]. However, despite this
treatment these tumors eventually progress and become
androgen-refractory within a few years [3]. Since 2004, the
first line treatment of advanced castration-resistant PCa
has been docetaxel, a microtubule stabilizing taxane, com-
bined with prednisone [4,5]. However, this combination
treatment strategy demonstrates a modest improvement
in overall survival and less than 20% of these patients at-
tain a 3-year survival rate [4,5]. Therefore, additionalentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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or metastatic stage.
An alternative strategy to the above-mentioned thera-
peutic approaches is immunotherapy. PCa is attractive as
a target for immunotherapy for multiple reasons: 1) the
presence of organ-specific tumor-associated antigens,
2) the initial slow-growing nature of the disease allowing
for adequate time for an anti-immune response to de-
velop, and 3) immunotherapy is relatively safe given the
dispensable nature of the organ [5,6]. This suggestion is
supported by the fact that an immunotherapeutic strategy
(sipuleucel T) was approved by the FDA in 2010 for the
treatment of metastatic, castration-resistant PCa [7].
Sipuleucel-T is an autologus vaccination strategy in which
peripheral blood mononuclear cells, including antigen
presenting cells (APC) are isolated from the patient and
are stimulated with a fusion protein consisting of prostatic
acid phosphatase and the immunostimulatory cytokine
granulocyte-macrophage colony-stimulating factor (GM-
CSF). These cells are then reinfused back into the patient.
This vaccination strategy has shown a survival advantage
over docetaxel-based treatments [4,5,7,8]. Another experi-
mental vaccination strategy (Prostvac-VF) consisting of
a recombinant vaccinia virus expressing the prostate-
specific antigen (PSA) and other co-stimulatory molecules
has also shown promise in clinical trials of PCa [4,5,8].
However, despite these significant advances, the continued
high rate of relapse and absence of a cure for metastatic
disease highlights the need for additional treatments for
PCa.
PSA is a 30 kDa glycoprotein serine protease expressed
by prostate epithelial cells that is normally confined to the
seminal fluid [9,10]. Only very small amounts of PSA
reach the circulatory system in healthy men [9,11,12].
However, due to structural changes in the cancerous
prostate, PSA is often found at high concentrations in the
blood of PCa patients, making it a useful diagnostic
marker. Different forms of PSA can be found in the blood,
including free PSA or PSA complexed to other proteins.
Free PSA accounts for approximately 15-20% of total
PSA. In the blood, PSA can form complexes with the
protease inhibitors α1-antichymotrypsin (ACT), α1-prote-
ase inhibitor (API), and α2-macroglobulin (A2M). The
monomeric ACT complex, composed of 1 PSA molecule
covalently linked to 1 ACT, is by far the most prevalent,
comprising nearly 80% of total PSA compared to 1-2%
for the A2M and API complexes [9-12]. PSA is a promi-
sing target for PCa immunotherapy because of its organ
specific production. In fact, a murine bispecific antibody
against human CD3 and human PSA has been shown to
mediate anti-tumor effects against prostate carcinoma
cells in vitro and in vivo [13]. Additionally, a rabbit IgG
antibody targeting human PSA was shown to preferen-
tially deliver a chemotherapeutic drug to PSA-expressingtumors in nude mice [14]. This immunoconjugate was
preferentially retained within the PCa tumors and en-
hanced cancer cell death, results that were not observed
in PCa tumors that did not express PSA [14]. Further-
more, the murine anti-PSA IgG1 (AR47.47) complexed
with PSA showed enhanced antigen presentation by hu-
man dendritic cells (DC) and induced both CD4 and CD8
T-cell activation [15], suggesting the possibility that this
antibody may interact with PSA in the blood of patients
redirecting this antigen into APC for antigen processing,
presentation, and T-cell activation against the tumor.
The efficacy of antibody therapies for the treatment of
cancer has been demonstrated in multiple cases [16,17].
Examples include trastuzumab (HerceptinW, a humanized
anti-HER2/neu IgG1) and rituximab (RituxanW, a mouse/
human chimeric anti-CD20 IgG1). Although most anti-
bodies used for cancer therapy are of the IgG class [16,17],
antibodies of the IgE class have various properties that may
be advantageous over IgG as potential cancer therapeutics.
These properties include 1) the low endogenous concen-
tration in serum (0.02% of circulating immunoglobulins
compared to 85% for IgG) that results in less competition
for FcR occupancy, 2) the lack of an inhibitory FcεR,
and 3) the superior affinity of IgE for its two FcεRs
relative to IgG and its FcγRs [18,19]. There are two human
FcεRs, the FcεRI that binds human IgE with high affinity
(Ka = 10
10 M-1) and is expressed on human basophils, mast
cells, monocytes, macrophages, eosinophils, Langerhans
cells, and DC, and the FcεRII (CD23) that binds IgE with
lower affinity (Ka = 10
8 M-1) and is expressed on hu-
man B cells, eosinophils, monocytes, macrophages, and DC
[18,20,21]. Importantly, IgE antibodies have been success-
fully used in animal models as passive cancer immunother-
apies and as adjuvants of cancer vaccines [22-25].
Given the relevance of PSA as a PCa antigen and the
attractive properties of the IgE molecule, our main goal
was to develop a mouse/human chimeric IgE antibody
containing the variable regions of the murine antibody
AR47.47. We now report the construction and expres-
sion of this novel antibody, as well as the evaluation of
its properties, including its potential anti-cancer activity.
We show its ability to bind the PSA antigen and the
FcεRI, to induce effector cell degranulation when effect-
ively cross-linked (but not in the presence of the natural
soluble antigen), and when complexed to PSA to induce
T-cell stimulation and anti-tumor activity in vivo.
Methods
Cell lines
Sp2/0-Ag14 murine myeloma cells were purchased from
ATCC (American Type Culture Collection, Manassas,
VA). The Chinese Hamster Ovary cell line (CHO-3D10)
expressing the human FcεRIα subunit [26] and the RBL
SX-38 rat basophil leukemic cell line expressing the full
Daniels-Wells et al. BMC Cancer 2013, 13:195 Page 3 of 13
http://www.biomedcentral.com/1471-2407/13/195human receptor (α, β, and γ subunits) [27] were kindly
provided by Dr. Jean-Pierre Kinet (Beth Israel Deaconess
Medical Center, Boston, MA). Murine CT26 colorectal car-
cinoma cells expressing and secreting human PSA (CT26-
PSA) [28] were kindly provided by Dr. John G. Frelinger
(University of Rochester Medical Center, Rochester, NY).
All cells were grown in IMDM media (Life Technologies
Corporation, Carlsbad, CA) supplemented with 100 U/mL
penicillin, 10 μg/mL streptomycin, and 10% (v/v) heat
inactivated fetal bovine serum (FBS; Atlanta Biologicals,
Atlanta, GA). Growth medium for CT26-PSA and RBL
SX-38 cells was additionally supplemented with 1 mg/mL
G418 (Life Technologies Corporation).
Development of recombinant anti-PSA antibodies
The mouse/human chimeric anti-human PSA IgG1 and
IgE were constructed using the DNA encoding the
variable regions of the murine IgG1 AR47.47 antibody
[15]. The VL and VH regions obtained by RT-PCR from
the hybridoma expressing AR47.47 were cloned into pCR-
BluntII-TOPO vectors (Life Technologies Corporation).
The DNA encoding the variable regions was then
subcloned into human κ light chain or the human ε (the
classic secreted isoform) [29] or γ1 heavy chain expression
vectors [30], respectively, all of which were obtained as
kind gifts from Dr. Sheri L. Morrison (University of
California at Los Angeles). The cloning strategy used
to develop both antibodies is shown in Additional file 1:
Figure S1. Both antibodies were expressed in the murine
myeloma cell line Sp2/0-Ag14, expanded in roller bottles,
and purified from cell culture supernatants. The anti-
human PSA IgE was purified using an immunoaffinity col-
umn containing anti-human IgE (omalizumab, XolairW,
Genentech, Inc. San Francisco, CA) coupled to cyanogen
bromide-activated Sepharose (GE Healthcare, Piscataway,
NJ) as recommended by the manufacturer. The chimeric
anti-human PSA IgG1 was purified using a Protein
A-Sepharose 4B, Fast Flow immunoaffinity matrix
(Sigma Aldrich, St. Louis, MO). A human HER2/neu
IgE [25] was produced in the same manner alongside the
anti-PSA IgE and was used as a non-PSA specific control
(NS IgE). Rituximab (RituxanW, a mouse/human chimeric
anti-CD20 IgG1; NS IgG) was obtained from Hoffman La
Roche (Indianapolis, IN). All antibodies were quantified
using the BCA Protein Assay (ThermoFisher Scientific
Inc., Walnut, CA).
Antigen binding (ELISA)
Immunolon H-2B plates (ThermoFisher Scientific, Inc.)
were coated with 5 μg/mL PSA or 10 μg/mL of the PSA
peptides containing amino acids (aa) 136–148 or 137–172,
which include the epitope recognized by the murine
monoclonal antibody AR47.47 [15]. The plates were incu-
bated at 4°C overnight, blocked in 3% BSA in PBS for 1hour at room temperature, and incubated at 4°C overnight
with various concentrations of purified anti-PSA IgE or a
NS IgE. Binding of the IgE was detected using an alkaline
phosphatase (AP)-conjugated anti-human κ-secondary
antibody and a phosphatase substrate. Absorbance at
405 nm was read on a DTX880 Multimode Detector
(Beckman Coulter, Fullerton, CA).
Binding to FcεRI (flow cytometry)
5×105 CHO-3D10 cells expressing human FcεRIα were
detached from tissue culture dishes using 0.5 mM EDTA
in PBS. Cells were incubated with either 1 μg NS IgG1
(negative control), NS IgE (positive control), or anti-PSA
IgE in 50 μL IMDM+ 10% FBS for 2 hours on ice. Sam-
ples were washed and binding to cells was detected by the
addition of an anti-human κ-FITC (BD Biosciences, San
Jose, CA). An anti-FcεRI phycoerythrin (PE)-conjugated
antibody (eBioscience, San Diego, CA) was tested simul-
taneously to verify receptor expression. Cells were fixed
with 2% paraformaldehyde and analyzed on a Becton
Dickinson FACScan Analytic Flow Cytometer in the
UCLA Jonsson Comprehensive Cancer Center and Center
for AIDS Research Flow Cytometry Core Facility. Histo-
grams were created using FCS express V3 (De Novo
Software, Los Angeles, CA).
HSA-PSA multi-epitope peptide construction and PSA
proteins
ChromPure human serum albumin (HSA) was purchased
from Jackson ImmunoResearch Laboratories, Inc (West
Grove, PA) and cross-linked using the sulfosuccinimidyl
4-[N-maleimidomethyl]cyclohexane-1-carboxylate (Sulfo-
SMCC; ThermoFisher Scientific Inc.) to a synthetic pep-
tide containing the AR47.47 binding site. Human albumin
was diluted in PBS to 2 mg/mL. Sulfo-SMCC was diluted
in 50 mM sodium phosphate buffer to a final concentra-
tion of 20 mM and added (20 μL) to human albumin. The
mixture was incubated for 30 minutes at room tempe-
rature. The reaction was stopped by adding 50 mM Tris,
pH 7.2. The PSA peptide was then added (1.56 mg) at a 1
to 10 molar ratio. After a 30-minute incubation, excess
cross-linker was removed using a Zeba spin desalting
column with a molecular weight cut-off of 7DK
(ThermoFisher Scientific, Inc.) equilibrated with PBS. Ex-
cess peptide was removed using a desalting column with a
cut-off of 10K. The HSA-PSA preparation was aliquoted
and stored at −80°C. Human PSA and the PSA-ACT com-
plex both purified from human blood/seminal fluid were
purchased from Lee Biosolutions, Inc. (St. Louis, MO).
In vitro degranulation assay
RBL SX-38 cells were detached using 0.5 mM EDTA in
PBS and 105 cells were added to wells of a 48-well plate
in 500 μL IMDM containing 10% FBS. Cells were
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1 μg/well anti-PSA IgE in assay buffer (5 mM KCl,
125 mM NaCl, 20 mM Hepes, 1.5 mM CaCl2, 1.5 mM
MgCl2; pH 7.4) or in assay buffer alone as a negative con-
trol. The plate was then incubated in standard tissue cul-
ture conditions for 2 hours. Various concentrations of
PSA, HSA-PSA (positive control), PSA-ACT, 10 μM cal-
cium ionophore (positive control; Millipore, Billerica,
MA), or assay buffer (negative control) were added and in-
cubated with the RBL SX-38 cells for an additional 2
hours. Degranulation was quantified by the amount of
β-hexosaminidase released into the cell supernatant. Using
a fresh 96-well plate, 100 μL of the substrate [2.5 mM
p-nitrophenyl-N-acetyl-β-D-glucosamine in 50 mM cit-
rate buffer (50 mM citric acid, 50 mM tribasic sodium cit-
rate, pH 4.5)] was added to 50 μL of supernatant for each
sample. Reactions were quenched by the addition of 100
μL sodium carbonate buffer (50 mM sodium carbonate,
50 mM sodium bicarbonate, pH 10). Absorbance at 405
nm was determined using a DTX880 Multimode detector
(Beckman Coulter, Fullerton, CA). β-hexosaminidase
release is expressed as a percentage of total basophil con-
tent as determined by separate treatment with 1% Triton
X-100 (maximum release). The percent degranulation was
determined by the following equation [(experimental
release – spontaneous release)/(maximum release –
spontaneous release)] × 100.
In vivo passive cutaneous (local) anaphylaxis
(hypersensitivity) assay
All experimental protocols were approved by the UCLA
Institutional Animal Care and Use Committee (IACUC).
Since human IgE does not interact with murine FcεRI
[20], BALB/c human FcεRIα transgenic mice were used
for this assay (a kind gift from Dr. Jean-Pierre Kinet,
Beth Israel Deaconess Medical Center, Boston, MA). In
these animals, the human FcεRIα replaces its murine
homolog and associates with murine FcεRIγ and FcεRIβ
chains resulting in a chimeric FcεRI that can be activated
by human IgE [31-33]. The expression of the FcεRI in
these animals mimics the expression pattern found in
humans with FcεRI being expressed on mast cells, eosin-
ophils, basophils, DC, Langerhans cells, macrophages,
and monocytes. It is important to note that these ani-
mals are not transgenic for human CD23, and thus only
express murine CD23 (which does not bind human IgE
[34]). The assay was performed essentially as previously
described [25]. Mice were injected intradermally with
PBS or 1 μg of anti-PSA IgE in a volume of 50 μL. After
4 hours, 25 μg anti-human κ (Sigma Aldrich), 50 μg
PSA, or 50 μg HSA-PSA was injected intraveneously in
1% Evans blue in PBS. The mice were euthanized after
10 minutes. Leakage of the blue dye into the skin is due
to a local IgE-induced inflammatory response. Color wasquantified using the NIH Image J Software and intensity
reported as the mean signal per pixel.In vitro antigen stimulation assay
This assay was performed as previously described [15,25].
Human peripheral blood mononuclear cells (PBMC) were
obtained from healthy donors. Monocytes were isolated
from the PBMC using the EasySep Human Monocyte En-
richment Negative Selection Kit (StemCell Technologies,
British Columbia, Canada). Monocytes were 89-96% pure
and were cultured for seven days in 4 ng/mL IL-4 and 0.1
ng/mL GM-CSF to differentiate them to DC, which were
then loaded with 2 μg/mL PSA mixed with various
amounts of either a NS IgG1 (0.5 to 2 μg/mL), anti-PSA
IgG1 (0.5 to 2 μg/mL), or equimolar amounts of anti-PSA
IgE (0.31-2.5 μg/mL). After loading for 4 hours, the DC
were matured with 0.18 ng/mL IFN-α and 10 ng/mL
TNF-α. DC were loaded with immune complexes prior to
maturation to maximize antigen uptake, since mature DC
favor antigen presentation over antigen uptake. Autolo-
gous T cells were isolated from PBMC using the EasySep
Human T Cell Negative Selection kit (StemCell Technolo-
gies) and were > 90% pure. These T cells were added to
cultures containing matured DC on day 8. T cells were in-
cubated for 7 days and restimulated with freshly pulsed
DC. T cells were stimulated (in vitro sensitization) for a
total of 3 rounds. During the last stimulation round, cells
were treated with Brefeldin A 4 hours after initiation of
the third stimulation to block cytokine secretion, and T
cells were harvested 18 hours later. These cells were then
stained for CD3, CD8 and intracellular IFNγ. Activation
of CD4 (CD3+/CD8-/IFN-γ+) and CD8 (CD3+/CD8+/
IFN-γ+) T cells was assessed by flow cytometry and ana-
lyzed using FlowJo (Tree Star, Inc).Vaccination study in human FcεR1α transgenic mice
Age-matched, male, human FcεRIα transgenic mice aged
7 to 13 weeks old were immunized with 4 μg PSA alone
or complexed in a 1:1 molar ratio with either anti-human
PSA IgG1 or anti-human IgE, injected subcutaneously in
the left flank (4 mice per group). Age-matched, male con-
trols were injected with buffer alone. Mice were boosted
2 weeks later (on day 15) in the same flank. Serum
was collected from all animals on days 14 and 28.
Mice were challenged on day 40 with 106 CT26-PSA cells
subcutaneously in the right flank. Tumor growth was
monitored using a caliper and animals were euthanized
when the tumors reached 1.5 cm in diameter. Survival
was recorded from the day of tumor challenge. The
Kaplan-Meier plot was generated using GraphPad Prism 4
(GraphPad Software Inc., La Jolla, CA). Significant differ-
ences in survival were determined using the Log Rank test
in GraphPad Prism.
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Figure 1 Binding to antigen and FcεRIα. A) Binding of the anti-PSA IgE compared to a NS IgE to PSA was detected by ELISA. B) Binding to the
known epitope recognized by AR47.47 was confirmed by ELISA using PSA peptides containing the antigen binding site. Binding was detected by
an AP-conjugated anti-human κ secondary antibody followed by a phosphatase substrate. ELISA data are the mean of triplicate samples with
standard deviations indicated and are representative of 3 independent experiments. C) Binding to the FcεRIα on the surface of CHO-3D10 cells
was detected using flow cytometry and an anti-human κ FITC-conjugated antibody. An anti-FcεRI PE-conjugated antibody was used
simultaneously to verify receptor expression. Data are representative of 3 independent experiments.
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serum of vaccinated mice
Blood from vaccinated animals was collected on days 14
and 28 and was allowed to clot at room temperature for
1 hour. Serum was collected after centrifugation at 3000
rpm for 10 minutes and stored at −80°C. For the ELISA,
Immunolon H-2B plates (ThermoFisher Scientific, Inc.)
were coated with 1 μg/mL human PSA. The plates were
incubated at 4°C overnight, washed 4 times in PBS,
blocked in 3% BSA in PBS for 1 hour at room tempe-
rature, and washed with 0.1% Tween-20 in PBS. For de-
tection of murine IgG1, mouse sera were serially diluted
3-fold starting at a dilution of 1:100 in 0.1% Tween-20
in PBS. Purified murine IgG1 AR47.47 (3-fold serial dilu-
tions starting at 100 ng/mL) served as the positive con-
trol, while the negative control sera was obtained from
unvaccinated animals (diluted in the same manner). The
presence of murine IgG1 specific for PSA was detected
using a rabbit anti-mouse IgG1 AP-conjugated antibody
(Life Technologies) and a phosphatase substrate (Sigma
Aldrich). Absorbance at 405 nm was read on a DTX880
Multimode Detector (Beckman Coulter). For detection
of murine IgG2a, sera were serially diluted 2-fold starting
at a 1:50 dilution in 0.1% Tween-20 in PBS. Negativecontrol sera were obtained from unvaccinated animals
and were prepared in the same manner. No murine IgG2a
specific for PSA was available for a positive control. Mur-
ine IgG2a antibodies were detected with an AP-
conjugated anti-mouse IgG2a (Life Technologies). Sera
were considered positive if absorbance values were greater
than 0.05 after a 2-hour incubation with substrate for
IgG1 or a 1-hour incubation for IgG2a (negative control
serum values ranged from 0.02-0.03). Significant increases
in titers were determined using the Fisher’s Exact prob-
ability test (GraphPad Software Quick Calcs Online Calcu-
lator for Scientists).
Results
Binding analysis
Both anti-PSA antibodies (IgG1 and IgE) were properly
assembled and secreted and showed the expected mo-
lecular weight of approximately 150 kDa and 190 kDa,
respectively (Additional file 1: Figure S1) [18]. The anti-
PSA IgE was shown by ELISA to bind the full-length
PSA protein (Figure 1A), as well as the known epitope
bound by AR47.47, which maps to the region of amino
acids 137–144 of PSA (Figure 1B) [15]. These studies
confirm that the AR47.47 variable regions are capable of
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Additionally, binding to the artificial HSA-PSA conju-
gate was also detected (data not shown). Furthermore,
flow cytometry analysis showed binding of the IgE to hu-
man FcεRIα expressed on the surface of CHO-3D10 cells
(Figure 1C). As expected similar levels of binding were
observed for a non-PSA specific human IgE (NS IgE)
indicating that the Fc region of the antibody is fully
functional with respect to FcεRIα binding.
IgE-induced degranulation of effector cells
In order to confirm that the human Fc region of the
targeted IgE is functional, its ability to induce degranula-
tion of FcεRI-bearing effector cells was evaluated. In the
allergic reaction, mast cells and basophils coated with
IgE rapidly degranulate in the presence of multi-epitopic
antigens, due to cross-linking of the FcεRI and the sub-
sequent Type I hypersensitivity/anaphylactic reaction
[35] (Figure 2 inset). However, if a mono-epitopic anti-
gen is present, the receptor is not expected to be cross-
linked and degranulation should not occur. Therefore,
we tested the two most abundant forms of PSA found in
the blood of PCa patients (the full PSA protein and
PSA-ACT), both of which interact with the anti-PSA IgE
in a mono-epitopic manner. Additionally, we tested an
artificial molecule (HSA-PSA) that consists of multiple
PSA peptides containing the epitope bound by AR47.475
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Figure 2 In vitro degranulation. Rat basophil leukemic cells expressing h
alone for 2 hours, followed by a 2-hour incubation with PSA, PSA-ACT, or H
concentration was adjusted to the equivalent molar amount of PSA-ACT (1
supernatants was monitored through the addition of 2.5 μM p-nitrophenyl
and standard deviation of triplicate samples are shown. Data are represent
compared to either component alone.conjugated to human serum albumin (HSA) to mimic a
multi-epitopic antigen. The anti-PSA IgE mediated de-
granulation of RBL SX-38 cells in vitro only when exposed
to HSA-PSA (Figure 2), but not PSA or PSA-ACT alone.
These data show that the Fc region of the antibody is
functional and can induce degranulation of effector cells
in the presence of a multi-epitopic antigen.
In vivo studies using human IgE can be hindered due
to various limitations as discussed [22], most notably the
lack of interaction of human IgE with murine FcεRI [20].
For this reason, BALB/c human FcεRIα transgenic mice
were used to evaluate the ability of the anti-PSA IgE to
induce degranulation of effector cells in vivo. In these
animals, the FcεRI is a chimeric receptor that can be ac-
tivated by human IgE with FcεRIα being of human origin
while both the FcεRIγ and FcεRIβ chains are of murine
origin [31-33]. A strong reaction was observed in the pres-
ence of the anti-PSA IgE when it was cross-linked using an
anti-human κ antibody (Figure 3A) or the artificial multi-
epitope form of the antigen, HSA-PSA (Figure 3B) indica-
ting that the IgE is able to mediate an acute inflammatory
(type I hypersensitivity) reaction in vivo. However, this in-
flammatory reaction was not observed in the presence of
PSA (Figure 3C) or PSA-ACT (data not shown). Color in-
tensity analysis assessed using the NIH ImageJ software
demonstrated that the mean color intensity of 3 animals in
the region where the anti-PSA IgE was injected was*
*
HSA-PSA (multi-epitopic)
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ng
8
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uman FcεRI (RBL SX-38) were sensitized with 1 μg of IgE or buffer
SA-PSA (an artificial PSA multi-epitope conjugate). The antigen
µg/mL or 0.1 µg/mL). The release of β-hexosaminidase into cell
-N-acetyl-β-D-glucosamine in 50 mM citrate buffer (pH 4.5). The mean
ative of 2 independent experiments * p < 0.01 (Student’s t-test)
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Figure 3 In vivo local, passive anaphylaxis in human FcεRIα
transgenic mice. Mice were injected intradermically on the back
with PBS alone, 1μg of PSA IgE or a NS IgE. After 4 hours, mice were
injected intravenously with either A) 25 μg anti-human κ, B) 50 μg
of the HSA-PSA peptide (containing multiple epitopes for AR47.47)
conjugate, or C) 50 μg PSA in 1% Evans blue in PBS. Animals were
euthanized 10 minutes later. A local hypersensitivity/anaphylactic
response (acute inflammatory reaction) caused by the degranulation
of FcεRI-expressing cells in the skin is visualized by leakage of the
dye into the skin due to vasodilation of local blood vessels.
Representative images of 3 independent experiments are shown.
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antibody or HSA-PSA (p < 0.01, Student’s t test). The mean
color intensity did not increase in the presence of PSA or
PSA-ACT (data not shown). These studies are consistent
with our in vitro degranulation studies and suggest that the
anti-PSA IgE would not cause a systemic hypersensitivity
(anaphylactic) reaction in the presence of the most abun-
dant forms of PSA in blood (free or complexed to ACT).
IgE-facilitated antigen stimulation
DC are potent APC that are capable of processing anti-
gens for presentation in the context of the major histo-
compatibility complexes I and II (MHC I and II) [36,37].
Thus, DC are capable of processing antigens via cross-
presentation leading to the activation of a cell-mediated
immune response. Human DC express both FcεRI and
FcεRII [20,21] and are able to interact with human IgE
bound to antigen [38-42]. IgE-facilitated antigen presen-
tation has been shown to occur through the binding of
human IgE to either FcεRI [39] or CD23 [42]. Processing
and presentation has also been shown to be required forthe activation of T cells through IgE-facilitated antigen
presentation [42]. Thus, we evaluated the ability of the
anti-PSA IgE to induce antigen presentation and T-cell ac-
tivation in vitro in human DC obtained from healthy indi-
viduals. DC pulsed with the IgE complexed with PSA
induced CD4 and CD8 T-cell activation (Figure 4).
Importantly, the activation of CD8 cells is indicative of
cross-presentation. DC pulsed with the anti-PSA IgG1
complexed to PSA also induced CD4 and CD8 T-cell acti-
vation, although to a lesser extent (Figure 4). Studies
conducted with cells isolated from 2 additional donors
also showed increased T-cell activation in the presence of
DC loaded with the anti-PSA IgE complexed with PSA.
Taken together, these data suggest that the anti-PSA IgE is
capable of enhancing antigen presentation in vitro.
Vaccination study
In order to evaluate the ability of the anti-PSA IgE to elicit
an immune response that would lead to anti-cancer acti-
vity in vivo, a vaccination strategy was employed. Sera
collected from the animals at day 14 and day 28 were ex-
amined for a murine anti-human PSA immune response.
Titers of both murine IgG1 (indicative of a TH2/humoral
response) and IgG2a (indicative of a TH1/cellular response
[43,44]) specific for PSA were determined. Vaccination
with human PSA alone resulted in the induction of an
IgG1 response in 5 out of 8 animals (Table 1). Following
vaccination with complexes of PSA and the anti-PSA
IgG1 or the anti-PSA IgE, all 8 animals developed a
murine IgG1 response (Table 1). After the initial im-
munization, only IgG1 titers were significantly higher in
animals vaccinated with complexes of the anti-PSA IgG1
and PSA (p = 0.041 with a titer greater than 900, Fisher
Exact test) compared to animals immunized with PSA
alone. However, after the booster, IgG1 levels were no lon-
ger significantly different. Murine IgG2a responses to PSA
were induced in 5 out of 8 animals vaccinated with PSA
alone (Table 2). Immunization with PSA complexed to the
anti-PSA IgG1 results in the same number of IgG2a posi-
tive animals, however, titers were low (Table 2). An IgG2a
response was observed in 7 out of 8 animals vaccinated
with PSA complexed to the anti-PSA IgE (Table 2). After
the booster, significantly higher titers of murine IgG2a
were observed in these mice (Table 2). These titers were
significantly higher compared to complexes of PSA and
the anti-PSA IgG1 (p = 0.001 with a titer greater than of
50) or compared to PSA alone (p = 0.041 with a titer
greater than 50, Fisher Exact test). An unusually high titer
of IgG2a was observed in 1 animal after the booster with
PSA alone. Interestingly, vaccination with the anti-PSA
IgE complexed to PSA significantly prolonged survival of
mice subcutaneously challenged two-weeks after the
booster (on day 40) with CT26-PSA cells (Figure 5,
Table 3). However, this protection was not observed with
CD8
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1.57 0.45
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γ
Figure 4 In vitro antigen stimulation assay. DC were generated from healthy donor monocytes using GM-CSF and IL-4. On Day 7, DC were
loaded with 2 μg/mL PSA and various concentrations of either a NS IgG1 or the anti-PSA IgG1. DC were also loaded with equimolar amounts of
the anti-PSA IgE antibody. Four hours after loading, the DC were matured with TNF-α and IFN-α. Autologous T cells were added 24 hours later.
Cells were incubated for 7 days and restimulated with freshly generated and pulsed DC weekly. The cells were stimulated for a total of 3 rounds.
One day after the third stimulation in the presence of Brefeldin A, T cells were harvested and analyzed for activation of CD4 and CD8 IFN-γ
producing T cells by intracellular cytokine staining and flow cytometry. CD3+/CD8- (CD4, left quadrants) and CD3+/CD8+ (CD8, right quadrants)
that stain positively for IFN-γ are a measure of specific activation.
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alone (Figure 5; Table 3).
Discussion
In general, most therapeutic antibodies used in the clinic to
treat malignancies are of the IgG class [16,17]. However,
the IgE class of antibodies may also be a meaningful option
for this purpose. In fact, a tumor targeted murine IgE spe-
cific for either the major envelope glycoprotein (gp36) of
mouse mammary tumor virus (MMTV) [45] or an anti-
genic determinant on the surface of human colon carcin-
oma cells [46] have shown anti-cancer effects in murine
models. Additionally, a mouse/human chimeric IgE
(MOv18 IgE) specific for the human ovarian cancer antigen
folate binding protein (FBP) demonstrated superior anti-
tumor activity in murine models compared to a mouse/hu-
man chimeric IgG1 with the same variable regions (MOv18
IgG1) [47,48]. This anti-cancer activity was only observed
in the presence of human PBMC or human monocytes,demonstrating that the Fc effector functions of the antibody
are required for the observed inhibitory activity [47-49].
Moreover, the MOv18 IgE was shown to mediate both
antibody-dependent cell-mediated cytotoxicity (ADCC)
and antibody-dependent cell-mediated phagocytosis
(ADCP) in vitro through the interaction of FcεRI and
CD23, respectively [50]. A humanized anti-HER2/neu IgE
with the variable regions of trastuzumab (HerceptinW) has
also been shown to trigger basophil degranulation and
ADCC in vitro in the presence of human HER2/neu ex-
pressing cells [51]. More recently, a fully human IgE also
targeting human HER2/neu with the variable regions of the
scFv C6MH3-B1 has been described and shown to have
in vivo anti-cancer activity in human FcεRIα transgenic
mice in a passive immunotherapeutic setting against a syn-
geneic tumor expressing human HER2/neu [25]. Com-
plexes of this IgE with its soluble antigen (ECDHER2)
demonstrated enhanced in vitro antigen presentation when
compared to an anti-HER2/neu IgG1 complexed to
Table 1 Murine anti-human PSA IgG1 titers in the serum
of vaccinated human FcεRIα transgenic mice
Titers 14 days after initial immunization
Mouse # PSA + anti-PSA IgE PSA + anti-PSA IgG1 PSA Buffer
1 8,100 100 900 0
2 2,700 24,300 0 0
3 900 8,100 0 0
4 2,700 24,300 0 0
5 2,700 24,300 2,700 0
6 900 72,900 8,100 0
7 24,300 8,100 900 0
8 900 2,700 900 0
Median 2,700 16,200 900 0
Titers 13 days after booster (28 days after initial immunization)
Mouse # PSA + anti-PSA IgE PSA + anti-PSA IgG1 PSA Buffer
1 218,700 8,100 24,300 0
2 218,700 72,900 0 0
3 72,900 24,300 0 0
4 218,700 218,700 0 0
5 72,900 400,000 218,700 0
6 72,900 218,700 218,700 0
7 24,300 218,700 8,100 0
8 218,700 24,300 72,900 0
Median 145,800 145,800 16,200 0
Data shown are combined from two independent experiments (n = 4) with a
total of 8 animals per group. Sera were serially diluted 3-fold starting at 1:100.
Titer was determined as the highest dilution from which a positive signal
was obtained.
Table 2 Murine anti-human PSA IgG2a titers in the serum
of vaccinated human FcεRIα transgenic mice
Titers 14 days after initial immunization
Mouse # PSA + anti-PSA IgE PSA + anti-PSA IgG1 PSA Buffer
1 0 0 0 0
2 0 0 0 0
3 200 0 0 0
4 0 0 0 0
5 0 0 50 0
6 0 0 0 0
7 0 0 0 0
8 100 0 0 0
Median 0 0 0 0
Titers 13 days after booster (28 days after initial immunization)
Mouse # PSA + anti-PSA IgE PSA + anti-PSA IgG1 PSA Buffer
1 0 0 1,600 0
2 200 0 50 0
3 200 50 0 0
4 800 0 0 0
5 200 50 400 0
6 400 50 0 0
7 100 50 50 0
8 100 50 50 0
Median 200 50 50 0
Data shown are combined from two separate experiments (n = 4) with a total
of 8 animals per group. Sera were serially diluted 2-fold starting at 1:50. Titer
was determined as the highest dilution from which a positive signal
was obtained.
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logical study carried out in Macaca fascicularis
(cynomolgus) monkeys and showed that this anti-HER2
/neu IgE was well-tolerated in this initial study at the 2
doses tested [25].
We now report the development of a mouse/human
chimeric IgE specific for PSA that contains the variable re-
gions of the murine antibody AR47.47 and binds the PSA
antigen and FcεRI. Cross-linking induced by either the
artificial HSA-PSA conjugate that contains multiple copies
of the AR47.47 epitope or the anti-human κ antibody
showed that this IgE is capable of inducing degranulation
of effector cells both in vitro and in vivo. However, de-
granulation of effector cells sensitized with the anti-PSA
IgE did not occur in the presence of the natural PSA pro-
tein or the PSA-ACT complex found in the blood which
carry a single binding epitope for AR47.47 per PSA mol-
ecule. We used a PSA concentration in our in vivo studies
that exceeds the amount of PSA found in human blood:
we injected 50 μg of protein per animal, which is equiva-
lent to 25–50 μg/mL, given the blood volume of a 18–25
gram mouse is 1–2 mL [52]. The median total PSA levelin the blood of normal human males varies with age but
ranges from 0.6-1.5 ng/mL [9,53]. Total PSA levels in the
blood of prostate cancer patients are usually much higher.
However, these levels are also highly variable (ranging
from 10–1000 ng/mL) [9]. Thus, even at the initial high
concentration in blood used for our studies, no reaction
was observed. Our data suggest that physiological or
pathological levels of PSA or PSA-ACT in the blood are
not likely to induce a systemic anaphylactic reaction if
combined with the anti-PSA IgE. It is important to note
that PSA can also be found in the blood of cancer patients
complexed with A2M and API, although these complexes
are present at very low levels [9-12]. Complexes of PSA
with API [54] have been shown to occur at a 1:1 ratio and,
therefore, should not induce a systemic reaction. Tetra-
meric A2M can bind two PSA molecules; however, the
A2M-PSA complex cannot be detected in the blood by
immunoassays since PSA is encapsulated by A2M [55-56].
Therefore, it is expected that the anti-PSA IgE would not
be able to bind the encapsulated PSA in this complex and
thus, it would not be expected to trigger a systemic ana-
phylactic reaction. Further studies are needed to
Days after CT26-PSA Challenge
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Figure 5 Vaccination study in human FcεRIα transgenic mice.
Survival plot of human FcεRIα transgenic mice vaccinated
subcutaneously in the left flank with PSA alone (4 μg) or complexed
in a 1:1 molar ration to either the anti-PSA IgE or IgG1. Mice were
given a booster on day 15, also in the left flank. Two-weeks after the
booster on day 40, mice were challenged with 106 murine CT26
cells expressing human PSA (CT26-PSA) subcutaneously in the right
flank. Animals admininstered with buffer alone were used as
negative controls. The survival plot shown is the combined data
from 2 independent experiments with a total of 8 mice per group
and was generated in GraphPad Prism.
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effector cells in the presence of the anti-PSA IgE as well
as the safety profile of this antibody.
Although the interaction with the anti-PSA IgE and nat-
urally occurring soluble forms of the antigen did not in-
duce degranulation of effector cells, immune complexes of
the IgE with the soluble antigen may interact with APC.
DC are potent APC that are capable of cross presentation.
DC are able to interact with human IgE bound to antigen
[38-42], including complexes consisting of mono-epitopic
interactions [57]. Both FcεRI [39] and CD23 [42] can medi-
ate IgE-facilitated antigen presentation. Previous studies
suggest that PSA is an appropriate target to mobilize T-cell
mediated immunity. PCa patients have been found toTable 3 Median survival of animals in the vaccination study i
Median
survival (days)
p-value
(compared to buffer contr
Buffer 14.5
PSA 15 0.777
PSA + anti-PSA IgG1 16 0.086
PSA + anti-PSA IgE 22 0.004
Data shown are combined from two independent experiments (n = 4 for each) withcontain naturally occurring IFN-γ producing CD8+ T-cells
that respond to PSA peptide in primary cultures [58]. Add-
itionally, a PSA DNA vaccine induced a robust PSA protein
and peptide specific T-cell response in 5 of 6 patients [59].
Furthermore, IgE has been shown to act as an adjuvant for
cancer therapy [24], making the anti-PSA IgE a meaningful
strategy to explore for the induction of a cell-mediated im-
mune response in PCa patients. In the present studies, en-
hanced in vitro activation of both CD4 and CD8 T cells
was observed when these cells were exposed to DC loaded
with the anti-PSA antibodies complexed to PSA. However,
cytotoxic T-cell (CTL) studies were not conducted. These
data are consistent with the enhanced presentation previ-
ously observed with complexes of the parental murine
anti-PSA antibody AR47.47 and PSA [15] and with the fact
that a T-cell response can be elicited in vitro in an antigen
stimulation assay using PBMC isolated from normal do-
nors [60]. However, T-cell activation was higher with IgE
immune complexes than what was observed with immune
complexes containing the mouse/human chimeric anti-
PSA IgG1. Enhanced antigen presentation with complexes
of an anti-HER2/neu IgE and the soluble antigen, com-
pared to complexes of the antigen and an anti-HER2/neu
IgG1 has also been previously observed in human DC
in vitro [25]. Importantly, the activation and expansion of
CD8 cells, indicative of cross-presentation, was only ob-
served in either case when DC were loaded with
complexes of the IgE or IgG1 with PSA. Complexes of
IgE and PSA were particularly efficient in cross-
presentation (CD8 T-cell activation). Taken together, these
results support the hypothesis that antigen-specfic IgE
can enhance antigen-specific T-cell immunity. How-
ever, further studies are needed to understand this
property and compare its ability to that of IgG1.
The in vivo vaccination studies show prolongation of sur-
vival in mice vaccinated with complexes of the anti-PSA
IgE and PSA as compared to buffer, PSA alone, or anti-PSA
IgG1 complexed with PSA. The effect, under these initial
conditions, is modest but significant, and the data show a
survival advantage with the vaccination strategy utilizing
complexes of IgE and its targeted antigen. Evaluation of the
murine anti-PSA response showed that murine IgG1 levels
are increased in all experimental groups. It is not surprising
that PSA alone induced a relevant IgG1 response since PSAn human FcεRIα transgenic mice
ol)
p-value
(compared to PSA)
p-value
(compared to PSA + anti-PSA IgG1)
0.147
0.005 0.01
a total of 8 animals per group.
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cinated with either the IgE or the IgG1 complexed to the
antigen were increased compared to PSA alone, consistent
with a stronger induction of a TH2 (humoral) immune re-
sponse. Additionally, in animals vaccinated with complexes
of the anti-PSA IgE and PSA, significantly higher titers of
murine IgG2a response were also observed. This suggests
that this vaccination strategy also induced a T-cell mediated
response (TH1) in these animals. Since this was the only
group to show significant protection from tumor challenge,
these findings may correlate with a preferential induction of
a TH1 response by vaccination with the complexes of the
anti-PSA IgE and the PSA antigen. Even though the in vivo
effects observed with the anti-PSA IgE were modest, the
observed anti-cancer effect may have clinical significance,
since the BALB/c strain used in these studies is biased
towards a TH2 response [61,62]. However, it is im-
portant to note that in our model system, the con-
stant regions of the anti-PSA IgE and IgG1 are of
human origin (xenotypic in the mouse) and that this
might influence the immunogenicity of PSA. Additional
studies are needed to further understand the observed
immunoactivation and anti-cancer activity in this model
as well as in other models.
Complexes of PSA with the anti-PSA IgG1 did not
show an anti-cancer effect in our particular vaccination
protocol. However, increased in vitro T-cell activation
was observed, even though it was to a lesser extent com-
pared to complexes of PSA with the IgE. The enhanced
T-cell activation by the anti-PSA IgG1 observed in this
study is consistent with a previous study that showed in-
creased PSA-specific T-cell activation in a vaccination
setting that used complexes of PSA and the anti-PSA
IgG1 in human PSA transgenic mice [63]. This study
demonstrated that the anti-PSA IgG1 is able to break
tolerance and suggests that in a therapeutic setting this
response can be further enhanced. Taken together, the
above data suggest that the anti-PSA IgE might also have
similar effects under tolerogenic conditions, a hypothesis
that could not be evaluated in the human PSA trans-
genic animal due to the lack of expression of human
FcεRIα.
It is tempting to speculate that the anti-PSA IgE can
also target PCa tumors and elict an acute inflammatory
reaction and thereby, enhance anti-tumor activity. Even
though PSA is a secreted antigen, it might be concen-
trated within the tumor microenvironment. For instance,
this may occur due to interactions with glycosaminogly-
cans on the surface of malignant cells or in the tumor
stroma through its heparin-binding activity. PSA has
two proposed heparin-binding sites [64] and has been
shown to bind heparin [65,66]. Previous studies have
shown that anti-PSA antibodies can have anti-cancer
activity in vitro and in vivo [13,14], suggesting that suchantibodies are able to target PCa tumors. In addition, a
radiolabeled anti-PSA monoclonal antibody was used
target PCa tumors in human for imaging purposes [67].
Thus, it is possible that the IgE antibody may also have
this activity. Further studies are needed to evaluate this
possibility.
Conclusions
The studies described here belong to the field of
AllergoOncology, which aims to evaluate IgE-mediated anti-
tumor immune responses with the goals of furthering our
understanding of the biology of IgE and developing IgE-
based cancer therapies. In this article, we describe the devel-
opment of a novel antibody of the IgE class that expands
this field and supports the notion that this anti-PSA IgE has
potential therapeutic value in humans. However, additional
evaluation of the anti-PSA IgE is warranted to further
understand both the anti-cancer effects and the safety profile
of the molecule.
Additional file
Additional file 1: Figure S1. Cloning strategy for production of the
mouse/human chimeric anti-PSA antibodies. The DNA encoding both the
light chain and heavy chain variable regions was obtained from hybridoma
cells expressing the murine anti-human PSA antibody AR47.47 and cloned
into pCR-BluntII-TOPO vectors. The DNA encoding the variable regions was
then subcloned into the respective expression vectors. To create the anti-PSA
IgG1, both the light chain κ and heavy chain γ1 expression vectors were
electroporated into the murine myeloma cell line Sp2/0-Ag14 . The DNA
encoding the heavy chain PSA variable region was further subcloned into
the IgE heavy chain expression vector and electroporated (together with the
PSA κ expression vector) into Sp2/0-Ag14 cells to produce the IgE antibody.
Both chimeric antibodies were properly assembled and secreted. The purified
antibodies show the expected molecular weight as demonstrated by SDS-
PAGE under both non-reducing and reducing conditions.
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